Cellectis S.A. released reporting its business objectives across its products pipeline and in-house manufacturing for 2022. In particular, the Company announced that it will focus on pursuing recruitment for its core ongoing clinical trials—BALLI—01 (for UCART22), AMELI-01 (for UCART123) and MELANI-01 (for UCARTCS1)—and the filing of an investigational new drug application (IND) for the first dual allogeneic UCART20x22. The Company also announced that its two manufacturing sites, in Raleigh, North Carolina and Paris, France, are now fully operational.

The Paris facility is focusing on plasmids and mRNA production for the Company's TALEN® gene editing tools. With respect to its Raleigh, North Carolina cGMP manufacturing facility, the Company announced that the qualification of the facility, equipment and systems was completed during the third quarter of 2021 and that manufacture and release batches of product candidates UCART22 and UCART20x22 have started in the third quarter of 2021. In light of the Company's announced operational focus, the Company (excluding Calyxt, Inc) anticipates that the cash, cash equivalents, and restricted cash of $201 million as of September 30, 2021 will fund its operations into early 2024.